Induced expression of dominant-negative c-jun downregulates NFκB and AP-1 target genes and suppresses tumor phenotype in human keratinocytes

Molecular Carcinogenesis

Volumn 29, Issue 3, 2000, Pages 159-169

  Li, Jian Jian ^a,b   Cao, Ya ^a,c   Young, Mathew R ^a   Colburn, Nancy H ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^c CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

Activator protein 1; Human keratinocytes; Inducible transgene; Neoplastic progression; Nuclear factor B

Indexed keywords

CELL DNA; COLLAGENASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1; INTERLEUKIN 6; PROTEIN C JUN; PROTEIN P53; STROMELYSIN; TRANSCRIPTION FACTOR AP 1;

ANCHORAGE INDEPENDENT GROWTH; ARTICLE; CANCER INHIBITION; CARCINOGENESIS; CELL TRANSFORMATION; CONTROLLED STUDY; DNA BINDING; DOWN REGULATION; ELECTROPHORETIC MOBILITY; GENE CONTROL; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; KERATINOCYTE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; REPORTER GENE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRANSACTIVATION; TRANSCRIPTION INITIATION; TUMOR GROWTH; TUMOR SUPPRESSOR GENE;

CELL ADHESION; CELL DIVISION; CELL LINE, TRANSFORMED; CELL TRANSFORMATION, NEOPLASTIC; DNA; DOWN-REGULATION; GENE EXPRESSION REGULATION; GENES, JUN; HUMANS; KERATINOCYTES; LUCIFERASES; NF-KAPPA B; PHENOTYPE; PROTO-ONCOGENE PROTEINS C-JUN; REPRESSOR PROTEINS; TRANS-ACTIVATION (GENETICS); TRANSCRIPTION FACTOR AP-1; TRANSCRIPTION FACTOR RELA; TRANSFECTION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0033646833     PISSN: 08991987     EISSN: None     Source Type: Journal    
DOI: 10.1002/1098-2744(200011)29:3<159::AID-MC5>3.0.CO;2-W     Document Type: Article

References (53)

1. Tumour promoter induces anchorage independence irreversibly
2. V-ras genes from Harvey and BALB murine sarcoma viruses can act as initiators of two-stage mouse skin carcinogenesis
3. Multistep carcinogenesis: A 1992 perspective
4. Multistage carcinogenesis in mouse skin
5. HPV16 E6 and E7 proteins cooperate to immortalize human foreskin keratinocytes
6. Complex formation of human papillomavirus E7 proteins with the retinoblastoma tumor suppressor gene product
7. Cotransfection of HPV-18 and v-fos DNA induces tumorigenicity of primary human keratinocytes
8. Inhibitors of both NF-kB and activator protein-1 activation blocks the neoplastic transformaiton response
9. Expression of dominant negative Jun inhibits elevated AP-1 and NF-kB transactivation and suppresses anchorage independent growth of HPV immortalized human keratinocytes
10. A dominant negative mutant of Jun blocks TPA-induced invasion independently of a direct effect on matrix metalloproteinase gene expression
11. Oncogene-initiated aberrant signaling engenders the metastatic phenotype: Synergistic transcription factor interctions are targets for cancer therapy
12. Cross-coupling of the NF-κB p65 and Fos/Jun transcription factors produces potentiated biological function
13. The inhibitory ankyrin and activator Rel proteins
14. Function and activation of NF-kappa B in the immune system
15. Kappa B site-dependent induction of gene expression by diverse inducers of nuclear factor kappa B requires Raf-1
16. Constitutive expression of lymphoma-associated NFKB-2/Lyt-10 proteins is tumorigenic in routine fibroblasts
17. Disruption of IκBα regulation by antisense RNA expression leads to malignant transformation
18. Ablation of transplanted HTLV-I Tax-transformed tumors in mice by antisense inhibition of NF-kappa B
19. Bionutrition and oral cancer in humans
20. A requirement for NF-kappaB activation in Bcr-Abl-mediated transformation
21. Expression of a dominant-negative mutant inhibitor-kappaBalpha of nuclear factor-kappaB in human head and neck squamous cell carcinoma inhibits survival, proinflammatory cytokine expression, and tumor growth in vivo
22. Alterations in NF-kappaB function in transgenic epithelial tissue demonstrate a growth inhibitory role for NF-kappaB
23. Transformation suppressor activity of a Jun transcription factor lacking its activation domain
24. Suppression of oncogene-induced transformation by a deletion mutant of c-Jun
25. Blocking of tumor promoter-induced AP-1 activity inhibits induced transformation in JB6 mouse epidermal cells
26. Transgenic mice demonstrate AP-1 (activator protein-1) transactivation is required for tumor promotion
27. Tight control of gene expression in mammalian cells by tetracycline responsive promoters
28. Inducible gene expression systems for higher eukaryotic cells
29. Tetracycline controlled gene expression system achieves high-level and quantitative control of gene expression
30. Inducible gene expression in mammalian cells and transgenic mice
31. Inhibition of tumor promoter induced transformation by retinoids that transrepress AP-1 without transactivating RARE
32. Dosage-dependent dominance over wild-type p53 of a mutant p53 isolated from nasopharyngeal carcinoma
33. Human papillomavirus type 18E6 mRNA in primary tumors and pelvic nodes of Hungarian patients with squamous cervical cancer
34. Different mechanisms of regulation of the human stromelysin and collagenase gene
35. T cell activation and increases in protein kinase C activity enhance retinoic acid-induced gene transcription
36. Comparison of human stromelysin and collagenase by cloning and sequence analysis
37. Quantitation of mRNA by the polymerase chain reaction
38. Quantitative keratinocyte assay detects two biological activities of human papillomavirus DNA and identifies viral associated with cervical carcinoma
39. Mechanism of action of a dominant-negative mutant of c-Jun
40. Dominant-negative mutants of cJun inhibit AP-1 activity through multiple mechanisms and with different potencies
41. Isolation of the oncogene and epidermal growth factor-induced transin gene: Complex control in rat fibroblasts
42. A novel metalloproteinase gene specifically expressed in stromal cells of breast carcinomas
43. Matrix metalloproteinase gene expression
44. Phorbol ester-inducible genes contain a common cis element recognized by a TPA-modulated trans-acting factor
45. NF-kappaB determines localization and features of cell death in epidermis
46. Increased expression of p50-NF-kappaB and constitutive activation of NF-kappaB transcription factors during mouse skin carcinogenesis
47. Antitumor promotion and antiinflammation: Down-modulation of AP-1 (Fos/Jun) actiivity by glucocorticoid hormone
48. NF-kB: A lesson in family values
49. Regulation of interleukin 1 and its receptor in human keratinocytes
50. JunB differs from c-Jun in its DNA-binding and dimerization domains, and represses c-Jun by formation of inactive heterodimers
51. Jun-B differs in its biological properties from, and is a negative regulator of, c-Jun
52. Stromelysin-3 induction and interstitial collagenase repression by retinoic acid. Therapeutical implication of receptor-selective retinoids dissociating transactivation and AP-1-mediated transrepression
53. The NF-kappa B and I kappa B proteins: New discoveries and insights